

## PROGRAM OVERVIEW

Continuing Education Company has been organizing its Primary Care Conference Series for over 30 years. The **32<sup>nd</sup> Annual Primary Care Conference, Session II** is designed to update primary care clinicians in rapidly changing therapeutic areas. The emphasis is on practical and useful information for clinical practice. This CME will educate and promote improved patient outcomes in a broad range of therapeutic areas commonly encountered in the primary care practice. It will highlight the latest science related to a variety of specialty areas, presented in a practical and patient-focused manner in the primary care setting. The *32<sup>nd</sup> Annual Primary Care Conference, Session II* will be held at Kiawah Island Golf Resort, West Beach Conference Center in Kiawah Island, South Carolina, July 1 - 5, 2024.

## LEARNING OBJECTIVES

As a result of this educational activity, participants should be better able to:

- Assess and provide patients with an accurate diagnosis and optimal care for a broad range of disorders seen in primary care.
- Utilize current guidelines in the diagnosis and management of commonly encountered therapeutic issues.
- Formulate comprehensive evidence-based interventions and treatment strategies that will lead to the reduction of risk factors and improved long-term outcomes.

## ACCREDITATION

**American Academy of Family Physicians:** The AAFP has reviewed the *32<sup>nd</sup> Annual Primary Care Conference, Session II* and deemed it acceptable for up to 20.00 live AAFP Prescribed credits. Term of Approval is from 07/01/2024 – 07/05/2024. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**AMA PRA Category 1 Credits™:** Continuing Education Company, Inc. (CEC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Continuing Education Company designates this live activity for a maximum of 20 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**ABIM MOC:** Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 20 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

## UNLABELED USE DECLARATION

During their presentation, faculty may discuss unlabeled or investigational use which is not approved for a commercial product. Faculty members are required to disclose this information to the audience when referring to an unlabeled or investigational use.

## STATEMENT OF DISCLOSURE AND INDEPENDENCE

It is the policy of Continuing Education Company (CEC) to ensure all of its accredited educational activities are designed, implemented, and evaluated in accordance with the Accreditation Council for Continuing Medical Education's (ACCME) Criteria and Policies. In accordance with ACCME requirements, CEC has Relevant Financial Relationship Disclosure Policies that are designed to ensure that accredited educational activities are fair, balanced, independent, evidence based, and based on scientific rigor.

All individuals who are in position to influence and/or control content of a CEC accredited Continuing Medical Education (CME) activity must disclose any financial interest or other relationships they have with an ineligible company, which is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. (Relevant financial interest or other relationship includes such things as grants or research support, employee, consultant, major stockholder, member of speakers' bureau, etc.) The intent of this disclosure is to provide activity participants with information to determine whether the speaker's interests or relationships may influence the presentation with regard to exposition or conclusions. **All relevant financial relationships have been identified, mitigated, and are listed below.**



The opinions, ideas, recommendations, and perspectives expressed in the syllabus and accompanying presentations at this activity are those of the program authors and presenting faculty only and do not necessarily reflect the opinions, ideas, recommendations or perspectives of their affiliated institutions, Continuing Education Company, advisory boards or consultants.

**REVIEW AND PLANNING COMMITTEE DISCLOSURES**

The following individuals have indicated that they have no financial relationships with an ineligible company that may impact upon this CME activity:

- Raymond E. Major, MD – Reviewer
- Walter Ejnes, CHCP – Reviewer & Planning Committee (Continuing Education Company)
- Lizzie Masters – Reviewer (Continuing Education Company)
- Beth Ryan Townsend, CHCP – Reviewer (Continuing Education Company)
- Su Barnwell – Planner (Continuing Education Company)

**FACULTY DISCLOSURES**

The following individuals were responsible for developing their own content, which has been reviewed by Continuing Education Company’s Medical Education Advisory Committee to ensure it is unbiased. Continuing Education Company has ensured that all relevant financial relationships that faculty may have with ineligible companies have been mitigated in advance of the CME activity. An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

<b>Faculty</b>	<b>Disclosures</b>	<b>Company</b>
Alan Baptist, MD	Research Grant	American Lung Association
	Consultant, Research Grant	Astra Zeneca
	Consultant, Research Grant	GSK
	Research Grant	Novartis
	Research Grant	Takeda
	Consultant	Teva
Jan Basile, MD	Research Grant	Ablative Solutions
	Consultant	Eli Lilly
	Consultant	Medtronic
	Consultant	Novo Nordisk
	Consultant, Research Grant	ReCor
	Consultant	UpToDate (Hypertension Section)
Danielle Campagne, MD	Consultant	EM:RAP
Jennifer Green, MD	Consultant	Anji
	Consultant	Astra Zeneca
	Consultant	Bayer
	Grant Recipient	Bluedrop
	Consultant, Grant Recipient	Boehringer Ingelheim
	Consultant, Grant Recipient	Lilly
	Research Grant	Merck
	Consultant	Novo Nordisk
	Research Grant	Roche
	Consultant	Valo
	Consultant	Vertex
Albert Hicks, MD	Consultant, Speaker’s Bureau	Boehringer Ingelheim

Erin Michos, MD	Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant	Amgen Arrowhead Pharmaceutical Astra Zeneca Boehringer Ingelheim Edwards Lifesciences Eli Lilly Esperion Ionis Pharmaceuticals Medtronic Merck New Amsterdam Novartis Novo Nordisk Pfizer
John Post, MD	Nothing to Disclose	
Julia Riddle, MD	Advisory Board, Ownership Interest	Cercle.ai
David Sadava, PhD	Nothing to Disclose	
C. Wayne Weart, PharmD	Nothing to Disclose	